Brokerages Anticipate Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Will Post Earnings of -$0.34 Per Share

Equities research analysts predict that Galmed Pharmaceuticals Ltd. (NASDAQ:GLMDGet Rating) will post earnings of ($0.34) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Galmed Pharmaceuticals’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.41). Galmed Pharmaceuticals reported earnings per share of ($0.38) in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.5%. The business is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Galmed Pharmaceuticals will report full year earnings of ($1.37) per share for the current financial year, with EPS estimates ranging from ($1.60) to ($1.20). For the next financial year, analysts anticipate that the company will report earnings of ($1.43) per share, with EPS estimates ranging from ($1.68) to ($1.17). Zacks’ EPS calculations are an average based on a survey of analysts that follow Galmed Pharmaceuticals.

GLMD has been the topic of several research reports. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 1st. StockNews.com began coverage on shares of Galmed Pharmaceuticals in a research note on Monday. They set a “sell” rating on the stock.

Shares of GLMD stock traded down $0.12 during trading hours on Tuesday, hitting $1.54. 108,603 shares of the company’s stock were exchanged, compared to its average volume of 104,711. The company has a market capitalization of $38.63 million, a PE ratio of -1.03 and a beta of 1.95. Galmed Pharmaceuticals has a 12-month low of $1.19 and a 12-month high of $4.08. The business’s 50 day simple moving average is $1.55 and its 200-day simple moving average is $2.05. The company has a current ratio of 6.88, a quick ratio of 6.88 and a debt-to-equity ratio of 0.01.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James & Associates increased its stake in shares of Galmed Pharmaceuticals by 10.5% in the third quarter. Raymond James & Associates now owns 229,640 shares of the biopharmaceutical company’s stock worth $641,000 after buying an additional 21,775 shares during the period. Morgan Stanley increased its position in Galmed Pharmaceuticals by 14.3% during the 1st quarter. Morgan Stanley now owns 185,552 shares of the biopharmaceutical company’s stock valued at $636,000 after purchasing an additional 23,200 shares during the period. Millennium Management LLC increased its position in Galmed Pharmaceuticals by 308.4% during the 4th quarter. Millennium Management LLC now owns 53,239 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 40,203 shares during the period. Virtu Financial LLC purchased a new position in Galmed Pharmaceuticals during the 4th quarter valued at $65,000. Finally, Geode Capital Management LLC increased its position in Galmed Pharmaceuticals by 36.2% during the 3rd quarter. Geode Capital Management LLC now owns 27,177 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 7,217 shares during the period. 13.48% of the stock is currently owned by institutional investors.

Galmed Pharmaceuticals Company Profile (Get Rating)

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

Read More

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.